PSTX צמיחת רווחי EPS רבעונית Poseida Therapeutics, Inc.
Poseida Therapeutics (PSTX) is implementing alcohol-free gene editing to create affordable and safe oncology drugs. Material delivery is carried out via proven ultra-cold chain logistics. The company targets the global personalized therapy market by supplying specialized clinics. The trend of quarterly earnings per share growth demonstrates the business results, where the value 159.60 describes the company's current efficiency level.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PSTX_-_Poseida-Therapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "poseida.com (PSTX): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 18.01.2025 | 👁️GURU.Markets👁️")
Poseida Corp (PSTX) - פילוחי מדדים ודוחות פיננסיים
The complexity of transporting Poseida Therapeutics (PSTX) gene therapies using liquid nitrogen directly impacts operating expenses and final margins. By analyzing the quarterly EPS growth efficiency metric on GURU.Markets, an investor can track net income per share, which allows for an assessment of financial plan execution accuracy and prevents overpaying for the asset in the absence of real liquidity growth.
